Ulrik Mouritzen

1.2k total citations
22 papers, 896 citations indexed

About

Ulrik Mouritzen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Oncology. According to data from OpenAlex, Ulrik Mouritzen has authored 22 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Ulrik Mouritzen's work include Diabetes Management and Research (6 papers), Diabetes Treatment and Management (6 papers) and CAR-T cell therapy research (4 papers). Ulrik Mouritzen is often cited by papers focused on Diabetes Management and Research (6 papers), Diabetes Treatment and Management (6 papers) and CAR-T cell therapy research (4 papers). Ulrik Mouritzen collaborates with scholars based in Denmark, Germany and United Kingdom. Ulrik Mouritzen's co-authors include Claus Christiansen, Birte K. Skrumsager, Ole Lander Svendsen, Stephan Christgau, László B. Tankó, Paul A. Cloos, Jean‐Marie Delaissé, Pernille Høegh-Andersen, Daniela Lamers and Ulrike Hövelmann and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Diabetes.

In The Last Decade

Ulrik Mouritzen

22 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulrik Mouritzen Denmark	14	206	201	200	197	192	22	896
F. P. Cantatore Italy	13	162 0.8×	226 1.1×	129 0.6×	101 0.5×	63 0.3×	44	832
Julien Collette Belgium	16	97 0.5×	199 1.0×	158 0.8×	59 0.3×	78 0.4×	32	673
Arturo P. Saavedra United States	14	113 0.5×	98 0.5×	227 1.1×	111 0.6×	282 1.5×	40	1.2k
Rebecca C. Johnson United States	7	54 0.3×	125 0.6×	189 0.9×	116 0.6×	70 0.4×	14	1.1k
G. M. Hall United Kingdom	10	222 1.1×	441 2.2×	81 0.4×	89 0.5×	143 0.7×	13	919
Kwi Young Kang South Korea	21	109 0.5×	677 3.4×	144 0.7×	311 1.6×	51 0.3×	66	1.3k
O Huber-Bruning Netherlands	18	100 0.5×	690 3.4×	176 0.9×	132 0.7×	50 0.3×	29	1.0k
Charles-Joël Menkès France	12	328 1.6×	189 0.9×	123 0.6×	67 0.3×	34 0.2×	41	824
Yeong Wook Song South Korea	19	87 0.4×	319 1.6×	138 0.7×	201 1.0×	39 0.2×	44	921
Bei Zhang China	13	54 0.3×	118 0.6×	192 1.0×	121 0.6×	305 1.6×	33	1.1k

Countries citing papers authored by Ulrik Mouritzen

Since Specialization

Citations

This map shows the geographic impact of Ulrik Mouritzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrik Mouritzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrik Mouritzen more than expected).

Fields of papers citing papers by Ulrik Mouritzen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrik Mouritzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrik Mouritzen. The network helps show where Ulrik Mouritzen may publish in the future.

Co-authorship network of co-authors of Ulrik Mouritzen

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrik Mouritzen. A scholar is included among the top collaborators of Ulrik Mouritzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrik Mouritzen. Ulrik Mouritzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chadjichristos, Christos, et al.. (2022). Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes. International Journal of Molecular Sciences. 23(2). 600–600. 12 indexed citations

Squires, Paul E., et al.. (2021). Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney. International Journal of Molecular Sciences. 22(6). 2809–2809. 9 indexed citations

Naimi, Rahim M., Mark Hvistendahl, Lotte Hahn Enevoldsen, et al.. (2019). Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. The Lancet. Gastroenterology & hepatology. 4(5). 354–363. 61 indexed citations

Kim, Dongjoon, Ulrik Mouritzen, Bjarne Due Larsen, & Sayon Roy. (2018). Inhibition of Cx43 gap junction uncoupling prevents high glucose-induced apoptosis and reduces excess cell monolayer permeability in retinal vascular endothelial cells. Experimental Eye Research. 173. 85–90. 27 indexed citations

Kim, Dongjoon, et al.. (2017). Administration of a gap junction coupler reduces retinal vascular cell loss associated with diabetic retinopathy. Investigative Ophthalmology & Visual Science. 58(8). 4030–4030. 1 indexed citations

Madsen, Andreas Nygaard, et al.. (2017). Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis. Journal of Hepatology. 66(1). S102–S102. 2 indexed citations

Hövelmann, Ulrike, et al.. (2017). Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 41(3). 531–537. 76 indexed citations

Ignatenko, Stanislav, Birte K. Skrumsager, & Ulrik Mouritzen. (2016). Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial. International Journal of Clinical Pharmacology and Therapeutics. 54(4). 243–252. 39 indexed citations

Schmidt, Henrik, Janet Brown, Ulrik Mouritzen, et al.. (2010). Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial. Clinical Cancer Research. 16(21). 5312–5319. 38 indexed citations

10.

Grünwald, Viktor, Ingrid M.E. Desar, John B.A.G. Haanen, et al.. (2010). A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncologica. 50(1). 121–126. 33 indexed citations

11.

Davis, Ian D., Richard Kefford, Michael Millward, et al.. (2009). Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research. 15(6). 2123–2129. 120 indexed citations

12.

Parkner, Tina, Stig Dyrskog, Tomas Laursen, et al.. (2009). Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(5). 414–420. 4 indexed citations

13.

Davis, Ian D., Richard Kefford, M.J. Millward, et al.. (2008). Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: Clinical data from a phase IIa study. Journal of Clinical Oncology. 26(15_suppl). 3042–3042. 6 indexed citations

14.

Schmidt, Henrik, et al.. (2008). Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: Results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC). Journal of Clinical Oncology. 26(15_suppl). 3041–3041. 5 indexed citations

15.

Ligthelm, Robert J., Ulrik Mouritzen, Helle Lynggaard, et al.. (2006). Biphasic Insulin Aspart Given Thrice Daily is as Efficacious as a Basal-Bolus Insulin Regimen with Four Daily Injections. Experimental and Clinical Endocrinology & Diabetes. 114(9). 511–519. 50 indexed citations

16.

Christgau, Stephan, László B. Tankó, Paul A. Cloos, et al.. (2004). Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause The Journal of The North American Menopause Society. 11(5). 508–518. 103 indexed citations

17.

Raz, Itamar, et al.. (2003). Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clinical Therapeutics. 25(12). 3109–3123. 19 indexed citations

18.

Tankó, László B., Ulrik Mouritzen, L. Warming, et al.. (2003). Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone. 32(6). 687–693. 34 indexed citations

19.

Mouritzen, Ulrik, et al.. (2003). Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Annals of the Rheumatic Diseases. 62(4). 332–336. 145 indexed citations

20.

Mouritzen, Ulrik, et al.. (2002). Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. Metabolism. 51(1). 69–74. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact